Clinical Trial: Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder

Brief Summary: A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ages 18-65).

Detailed Summary: The Compulsive, Impulsive and Anxiety Disorders Program at the Mount Sinai School of Medicine is conducting a study of Topiramate (Topamax) added to an SSRI for the management of treatment-resistant Obsessive-Compulsive Disorder. The purpose of the study is to evaluate the safety and efficacy of Topiramate versus placebo added to a selective serotonin reuptake inhibitor (SRI) in patients with treatment resistant OCD. The program is 12 weeks in duration and involves regular visits with a psychiatrist as well as complete psychiatric and medical evaluations. Treatment and medication for the study will be provided free of charge.Participants must be between the ages of 18 and 65 and have an onset of OCD at least 1 year prior to screening. In addition, participants must be taking a clinically effective dose of an SSRI for at least 3 months and must maintain their current dose throughout the study. Participants must not have a primary OCD symptom of hoarding.
Sponsor: Icahn School of Medicine at Mount Sinai

Current Primary Outcome: To evaluate the safety and efficacy of adjunctive topiramate vs. placebo in the treatment of OCD

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Icahn School of Medicine at Mount Sinai

Dates:
Date Received: September 13, 2005
Date Started: August 2004
Date Completion: August 2006
Last Updated: September 5, 2008
Last Verified: December 2005